表紙
市場調查報告書

表皮生長因子受體(EGFR)抑制劑的全球市場:2019年∼2023年

Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market 2019-2023

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 877610
出版日期 內容資訊 英文 130 Pages
訂單完成後即時交付
價格
Back to Top
表皮生長因子受體(EGFR)抑制劑的全球市場:2019年∼2023年 Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market 2019-2023
出版日期: 2019年06月13日內容資訊: 英文 130 Pages
簡介

近年來,由於老年人口的增加和生活方式的改變,各種類型癌症的患病率顯著增加。市場目睹對用於治療癌症適應症新療法的巨大未滿足需求。這為供應商創造了巨大的機會,可以研究用於治療癌症的EGFR抑製劑等藥物。因此,在預測期內,主要癌症適應症的大量流行將導致全球EGFR抑製劑市場的成長率達到近9%的年複合成長率。

本報告提供全球表皮生長因子受體(EGFR)抑制劑市場相關調查分析,市場規模及成長率,市場趨勢,市場的推動要素與課題,市場機會驗證,再加上主要供應商等相關的系統性資訊。

目錄

第1章 摘要整理

第2章 調查範圍

  • 簡介1
  • 簡介2
  • 美金的貨幣換算比率

第3章 市場情形

  • 市場生態系統
  • 市場特徵
  • 市場區隔分析

第4章 市場規模

  • 市場定義
  • 市場規模(2018年)
  • 市場規模及預測(2018年∼2023年)

第5章 波特的五力分析

  • 買主談判力
  • 供應商談判力
  • 新加入廠商的威脅
  • 替代品的威脅
  • 競爭對手的威脅
  • 市場情況

第6章 市場區隔:各症狀

  • 市場區隔:各表示
  • 各症狀比較:市場規模及預測(2018年∼2023年)
  • 肺癌
  • 大腸癌
  • 乳癌
  • 其他
  • 市場機會:各前兆

第7章 客戶形勢

第8章 各地區形勢

  • 各地區市場區隔
  • 各地區比較:市場規模及預測(2018年∼2023年)
  • 北美
  • 歐洲
  • 亞洲
  • 其他地區
  • 主要國家
  • 市場機會

第9章 決策架構

第10章 成長要素與課題

  • 市場成長要素
  • 市場課題

第11章 市場趨勢

第12章 業者情勢

  • 概要
  • 創造性破壞狀況
  • 競爭模式

第13章 供應商分析

  • 交易廠商
  • 供應商分類
  • 供應商的市場定位
  • Amgen Inc.
  • AstraZeneca Plc
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG

第14章 附錄

  • 調查方法
  • 簡稱的清單
  • 供應商的市場定位定義

第15章 關於TECHNAVIO

目錄
Product Code: IRTNTR31465

About this market

The epidermal growth factor receptor (EGFR) is a protein-coding gene. It is found in high levels on cancer cells and is known to be responsible for the uncontrolled cell growth Inhibiting or blocking the growth of EGFR can stop the growth of cancer cells for long durations of time. Technavio's epidermal growth factor receptor inhibitors market analysis considers the revenue based on indications such as lung cancer, colorectal cancer, breast cancer, and others. Our analysis also finds the sales of the epidermal growth factor receptor inhibitors in North America, Europe, Asia, and ROW. In 2018, lung cancer had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the substantial prevalence of the disease will play a vital role in the lung cancer segment to maintain its market position. Also, our global epidermal growth factor receptor inhibitors market report looks at factors such as the substantial prevalence of major cancer indications, increasing awareness campaigns, and research funding. However, the high treatment costs, high preference for alternative therapies, and patent cliff may hamper the growth of the epidermal growth factor receptor inhibitors industry over the forecast period.

Overview

Strong prevalence of major cancer indications

The prevalence of various types of cancers has increased at a significant rate in recent years, owing to increasing geriatric population and changing lifestyle. The market is witnessing the vast unmet need for novel therapies for the treatment of cancer indications. This is creating huge opportunities for vendors to conduct studies on drugs such as EGFR inhibitors for the treatment of cancer. Thus, the substantial prevalence of major cancer indications will lead to the growth of the global EGFR inhibitors market at a CAGR of almost 9% during the forecast period.

New research areas

EGFR inhibitors are considered to be highly effective for the treatment of various types of cancer indications, which is encouraging researchers to study its use in the treatment of inflammatory and monogenic diseases. Hence, the new research areas of EGFR inhibitors are identified as a critical trend that will have a positive impact on the growth of the EGFR inhibitors market during the forecast period.

For the detailed list of factors that will drive the global epidermal growth factor receptor inhibitors market during the forecast period 2019-2023.

Competitive Landscape

With the presence of a few significant players, the global epidermal growth factor receptor inhibitors market is concentrated. Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading epidermal growth factor receptor inhibitors manufacturers, that include Amgen Inc., AstraZeneca Plc, Eli Lilly and Co., F. Hoffmann-La Roche Ltd., and Novartis AG.

Also, the epidermal growth factor receptor inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all future growth opportunities.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY INDICATION

  • Market segmentation by indication
  • Comparison by indication
  • Lung cancer - Market size and forecast 2018-2023
  • Colorectal cancer - Market size and forecast 2018-2023
  • Breast cancer - Market size and forecast 2018-2023
  • Others - Market size and forecast 2018-2023
  • Market opportunity by indication

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Amgen Inc.
  • AstraZeneca Plc
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

List of Exhibits

  • Exhibit 01:Global pharmaceuticals market
  • Exhibit 02:Segments of global pharmaceuticals market
  • Exhibit 03:Market characteristics
  • Exhibit 04:Market segments
  • Exhibit 05:Market definition - Inclusions and exclusions checklist
  • Exhibit 06:Market size 2018
  • Exhibit 07:Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 08:Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 09:Five forces analysis 2018
  • Exhibit 10:Five forces analysis 2023
  • Exhibit 11:Bargaining power of buyers
  • Exhibit 12:Bargaining power of suppliers
  • Exhibit 13:Threat of new entrants
  • Exhibit 14:Threat of substitutes
  • Exhibit 15:Threat of rivalry
  • Exhibit 16:Market condition - Five forces 2018
  • Exhibit 17:Indication - Market share 2018-2023 (%)
  • Exhibit 18:Comparison by indication
  • Exhibit 19:Lung cancer - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 20:Lung cancer - Year-over-year growth 2019-2023 (%)
  • Exhibit 21:Colorectal cancer - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 22:Colorectal cancer - Year-over-year growth 2019-2023 (%)
  • Exhibit 23:Breast cancer - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 24:Breast cancer - Year-over-year growth 2019-2023 (%)
  • Exhibit 25:Others - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 26:Estimated number of new cancer cases and deaths in the US - 2019
  • Exhibit 27:Others - Year-over-year growth 2019-2023 (%)
  • Exhibit 28:Market opportunity by indication
  • Exhibit 29:Customer landscape
  • Exhibit 30:Market share by geography 2018-2023 (%)
  • Exhibit 31:Geographic comparison
  • Exhibit 32:North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 33:North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 34:Top 3 countries in North America
  • Exhibit 35:Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 36:Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 37:Top 3 countries in Europe
  • Exhibit 38:Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 39:Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 40:Top 3 countries in Asia
  • Exhibit 41:ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 42:ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 43:Top 3 countries in ROW
  • Exhibit 44:Key leading countries
  • Exhibit 45:Market opportunity
  • Exhibit 46:Estimated new cancer cases and deaths in US 2019
  • Exhibit 47:Organizations conducting awareness campaigns
  • Exhibit 48:Impact of drivers and challenges
  • Exhibit 49:Global EGFR inhibitors market: pipeline
  • Exhibit 50:Vendor landscape
  • Exhibit 51:Landscape disruption
  • Exhibit 52:Vendors covered
  • Exhibit 53:Vendor classification
  • Exhibit 54:Market positioning of vendors
  • Exhibit 55:Amgen Inc. - Vendor overview
  • Exhibit 56:Amgen Inc. - Business segments
  • Exhibit 57:Amgen Inc. - Organizational developments
  • Exhibit 58:Amgen Inc. - Geographic focus
  • Exhibit 59:Amgen Inc. - Key offerings
  • Exhibit 60:Amgen Inc. - Key customers
  • Exhibit 61:AstraZeneca Plc - Vendor overview
  • Exhibit 62:AstraZeneca Plc - Business segments
  • Exhibit 63:AstraZeneca Plc - Organizational developments
  • Exhibit 64:AstraZeneca Plc - Geographic focus
  • Exhibit 65:AstraZeneca Plc - Key offerings
  • Exhibit 66:AstraZeneca Plc - Key customers
  • Exhibit 67:Eli Lilly and Co. - Vendor overview
  • Exhibit 68:Eli Lilly and Co. - Business segments
  • Exhibit 69:Eli Lilly and Co. - Organizational developments
  • Exhibit 70:Eli Lilly and Co. - Geographic focus
  • Exhibit 71:Eli Lilly and Co. - Segment focus
  • Exhibit 72:Eli Lilly and Co. - Key offerings
  • Exhibit 73:Eli Lilly and Co. - Key customers
  • Exhibit 74:F. Hoffmann-La Roche Ltd. - Vendor overview
  • Exhibit 75:F. Hoffmann-La Roche Ltd. - Business segments
  • Exhibit 76:F. Hoffmann-La Roche Ltd. - Organizational developments
  • Exhibit 77:F. Hoffmann-La Roche Ltd. - Geographic focus
  • Exhibit 78:F. Hoffmann-La Roche Ltd. - Segment focus
  • Exhibit 79:F. Hoffmann-La Roche Ltd. - Key offerings
  • Exhibit 80:F. Hoffmann-La Roche Ltd. - Key customers
  • Exhibit 81:Novartis AG - Vendor overview
  • Exhibit 82:Novartis AG - Business segments
  • Exhibit 83:Novartis AG - Organizational developments
  • Exhibit 84:Novartis AG - Geographic focus
  • Exhibit 85:Novartis AG - Segment focus
  • Exhibit 86:Novartis AG - Key offerings
  • Exhibit 87:Novartis AG - Key customers
  • Exhibit 88:Validation techniques employed for market sizing
  • Exhibit 89:Definition of market positioning of vendors
Back to Top